## Hazem Elewa

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7944306/hazem-elewa-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57	1,202	15	34
papers	citations	h-index	g-index
60	1,426 ext. citations	5	4.37
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
57	Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management <i>Current Problems in Cardiology</i> , <b>2022</b> , 101128	17.1	
56	Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review <i>International Journal of Clinical Pharmacy</i> , <b>2022</b> , 1	2.3	1
55	Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	2
54	The Dilemma of Peri-Procedural Warfarin Management: A Narrative Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211012093	3.3	
53	Drive-up INR testing and phone-based consultations service during COVID-19 pandemic in a pharmacist-lead anticoagulation clinic in Qatar: Monitoring, clinical, resource utilization, and patient- oriented outcomes. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2021</b> , 4, 1117	1.4	О
52	Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. <i>International Journal of Cardiology</i> , <b>2021</b> , 331, 27-34	3.2	1
51	Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100816	17.1	1
50	Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 388-396	5.1	22
49	Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 701-702	5.1	1
48	Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 297-300	5.1	5
47	Genetic Polymorphism Effect on Warfarin-Rifampin Interaction: A Case Report and Review of Literature. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 149-156	2.1	1
46	Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , <b>2021</b> , 17, 2397-2419	3.1	1
45	Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1069-1080	2.1	
44	Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100839	17.1	О
43	Vancomycin therapeutic drug monitoring service quality indices and clinical effectiveness outcomes: A retrospective cohort and clinical audit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2020</b> , 3, 778-785	1.4	2
42	Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 201-211	2.6	10
41	Effect of SAMe-TTR score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 659-666	5.1	1

40	The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 277-284	3.5	7
39	Evaluation of the Validity of SAMe-TTR Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620945039	3.3	1
38	Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, e242-e249	3.5	5
37	Assessing Pharmacists Knowledge and Attitude Toward the Direct Oral Anticoagulants in Qatar. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620933946	3.3	O
36	Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 957-968	5.1	3
35	Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 598846	5.4	13
34	Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619872554	3.3	2
33	The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619875520	3.3	2
32	Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619849103	3.3	6
31	Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2019</b> , 44, 639-652	2.7	11
30	Pharmacogenomics In Pharmacy Practice: Current Perspectives. <i>Integrated Pharmacy Research &amp; Practice</i> , <b>2019</b> , 8, 97-104	4.4	9
29	Exploring the Influence of Language on Assessment Given a Mismatch Between Language of Instruction and Language of Practice. <i>Simulation in Healthcare</i> , <b>2019</b> , 14, 271-275	2.8	
28	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. <i>Annals of Pharmacotherapy</i> , <b>2018</b> , 52, 185-197	2.9	3
27	Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 384	4	3
26	Approaches to Direct Oral Anticoagulant Selection in Practice. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 1074248418793137	2.6	4
25	Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 155-161	2.6	8
24	A Survey on the Awareness and Attitude of Physicians on Direct Oral Anticoagulants in Qatar. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 255S-260S	3.3	4
23	A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2017</b> , 42, 745-756	2.7	22

22	Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 118	4	7
21	Trends in oral anticoagulant use in Qatar: a 5-year experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 411-416	5.1	18
20	Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2017</b> , 22, 347-355	2.6	9
19	Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. <i>Drugs in R and D</i> , <b>2017</b> , 17, 341-361	3.4	14
18	The first pharmacist-managed anticoagulation clinic under a collaborative practice agreement in Qatar: clinical and patient-oriented outcomes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2016</b> , 41, 403-8	2.2	12
17	Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar. Journal of Evaluation in Clinical Practice, <b>2016</b> , 22, 433-8	2.5	15
16	The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168732	3.7	20
15	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2016</b> , 42, 662-70	5.3	11
14	Cancer-Associated Venous Thromboembolism. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2016</b> , 18, 23	2.1	8
13	Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. <i>SpringerPlus</i> , <b>2016</b> , 5, 8		8
12	Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1223-35	6.2	28
11	A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. <i>Journal of Evaluation in Clinical Practice</i> , <b>2015</b> , 21, 703-9	2.5	31
10	Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 38, 115-20	5.1	17
9	Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes. <i>International Journal of Hematology</i> , <b>2014</b> , 100, 119-24	2.3	18
8	A pharmacogenetic versus a clinical algorithm for warfarin dosing. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2283-93	59.2	547
7	Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). <i>Circulation: Cardiovascular Genetics</i> , <b>2010</b> , 3, 548-55		30
6	Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2009</b> , 330, 532-40	4.7	39
5	Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. <i>Stroke</i> , <b>2009</b> , 40, 1870-6	6.7	48

## LIST OF PUBLICATIONS

4	Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 326, 773-82	4.7	59
3	Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2008</b> , 86, 358-64	2.4	17
2	Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. <i>BMC Neurology</i> , <b>2007</b> , 7, 33	3.1	95
1	Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice. <i>Journal of Pharmacy Practice</i> , <b>2007</b> , 20, 117-122	1.3	